Popular Filters
Trials for Kidney Cancer Patients
Cyclin-Dependent Kinase Inhibitor
NKT2152 + Palbociclib + Sasanlimab for Kidney Cancer
Recruiting1 awardPhase 2
Omaha, Nebraska
This trial is testing a new drug combination for patients with advanced kidney cancer who have already tried other treatments. The goal is to see if these drugs can work better together to stop cancer growth and help the immune system fight the disease.
HIF2α Inhibitor
Oral NKT2152 for Kidney Cancer
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial is testing NKT2152, a new oral drug, in adults with a specific type of kidney cancer who have no other treatment options. It aims to find the safest dose and see if the drug can effectively fight the cancer.
Trials for Kidney Cell Carcinoma Patients
Cyclin-Dependent Kinase Inhibitor
NKT2152 + Palbociclib + Sasanlimab for Kidney Cancer
Recruiting1 awardPhase 2
Omaha, Nebraska
This trial is testing a new drug combination for patients with advanced kidney cancer who have already tried other treatments. The goal is to see if these drugs can work better together to stop cancer growth and help the immune system fight the disease.
HIF2α Inhibitor
Oral NKT2152 for Kidney Cancer
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial is testing NKT2152, a new oral drug, in adults with a specific type of kidney cancer who have no other treatment options. It aims to find the safest dose and see if the drug can effectively fight the cancer.
Trials With No Placebo
Cyclin-Dependent Kinase Inhibitor
NKT2152 + Palbociclib + Sasanlimab for Kidney Cancer
Recruiting1 awardPhase 2
Omaha, Nebraska
This trial is testing a new drug combination for patients with advanced kidney cancer who have already tried other treatments. The goal is to see if these drugs can work better together to stop cancer growth and help the immune system fight the disease.
Cryoablation
Cryoablation-Assisted Surgery for Kidney Cancer
Recruiting1 award2 criteria
Miami Lakes, Florida
This trial will compare two methods of controlling blood loss during surgery for kidney cancer: renal cryoablation (freezing the tumor) and selective arterial renal ischemia (restricting blood flow to the kidney).
HIF2α Inhibitor
Oral NKT2152 for Kidney Cancer
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial is testing NKT2152, a new oral drug, in adults with a specific type of kidney cancer who have no other treatment options. It aims to find the safest dose and see if the drug can effectively fight the cancer.
Small Molecule
DFF332 + Combination Therapy for Renal Cell Carcinoma
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing a new drug called DFF332 in patients with advanced kidney cancer and other cancers with certain genetic mutations. The drug works by blocking a protein that helps the cancer grow.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.